Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
2003 1
2004 2
2005 1
2012 1
2013 2
2014 1
2015 1
2021 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Organised assistance to suicide in England?
Rehmann-Sutter C, Hagger L. Rehmann-Sutter C, et al. Among authors: hagger l. Health Care Anal. 2013 Jun;21(2):85-104. doi: 10.1007/s10728-011-0191-y. Health Care Anal. 2013. PMID: 21901423
Autonomy and audit--striking the balance.
Hagger L, Woods S, Barrow P. Hagger L, et al. Med Law Int. 2004;6(2):105-16. doi: 10.1177/096853320400600203. Med Law Int. 2004. PMID: 16622965
Protease inhibitor monotherapy for long-term management of HIV infection: a randomised, controlled, open-label, non-inferiority trial.
Paton NI, Stöhr W, Arenas-Pinto A, Fisher M, Williams I, Johnson M, Orkin C, Chen F, Lee V, Winston A, Gompels M, Fox J, Scott K, Dunn DT; Protease Inhibitor Monotherapy Versus Ongoing Triple Therapy (PIVOT) Trial Team. Paton NI, et al. Lancet HIV. 2015 Oct;2(10):e417-26. doi: 10.1016/S2352-3018(15)00176-9. Epub 2015 Sep 14. Lancet HIV. 2015. PMID: 26423649 Free PMC article. Clinical Trial.
Long-term efficacy and safety of a treatment strategy for HIV infection using protease inhibitor monotherapy: 8-year routine clinical care follow-up from a randomised, controlled, open-label pragmatic trial (PIVOT).
Paton NI, Stöhr W, Arenas-Pinto A, Clarke A, Williams I, Johnson M, Orkin C, Chen F, Lee V, Winston A, Gompels M, Fox J, Sanders K, Dunn DT; Protease Inhibitor monotherapy Versus Ongoing Triple therapy (PIVOT) Trial Team. Paton NI, et al. EClinicalMedicine. 2024 Feb 10;69:102457. doi: 10.1016/j.eclinm.2024.102457. eCollection 2024 Mar. EClinicalMedicine. 2024. PMID: 38361989 Free PMC article.
Guidance in social and ethical issues related to clinical, diagnostic care and novel therapies for hereditary neuromuscular rare diseases: "translating" the translational.
McCormack P, Woods S, Aartsma-Rus A, Hagger L, Herczegfalvi A, Heslop E, Irwin J, Kirschner J, Moeschen P, Muntoni F, Ouillade MC, Rahbek J, Rehmann-Sutter C, Rouault F, Sejersen T, Vroom E, Straub V, Bushby K, Ferlini A. McCormack P, et al. Among authors: hagger l. PLoS Curr. 2013 Jan 10;5:ecurrents.md.f90b49429fa814bd26c5b22b13d773ec. doi: 10.1371/currents.md.f90b49429fa814bd26c5b22b13d773ec. PLoS Curr. 2013. PMID: 23330068 Free PMC article.
12 results